News & Updates
Filter by Specialty:
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
20 Dec 2022
Metformin may reduce COVID-19 severity in prediabetes, PCOS
Among patients with prediabetes or polycystic ovary syndrome (PCOS), the use of metformin appears to be associated with lower incidence of severe COVID-19, according to a study.
Metformin may reduce COVID-19 severity in prediabetes, PCOS
19 Dec 2022
Bepirovirsen shows promise in controlling chronic HBV infection
Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.
Bepirovirsen shows promise in controlling chronic HBV infection
19 Dec 2022
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
Maintenance olaparib confers survival benefit for HRD+ ovarian cancer patients
19 Dec 2022
One in eight adults experiences long COVID
One in every eight individuals who has experienced COVID-19 may have persistent symptoms 3–5 months post-infection, according to an observational study from the Netherlands.